Keytruda (Pembrolizumab) for Cancer Treatment
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Keytruda (pembrolizumab) is a humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 on T cells and its ligands PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses. It is one of the most broadly approved cancer immunotherapy agents, with indications spanning non-small cell lung cancer (NSCLC), melanoma, gastric/gastroesophageal junction cancer, cervical cancer, hepatocellular carcinoma, colorectal cancer (MSI-H/dMMR), urothelial carcinoma, triple-negative breast cancer, endometrial cancer, and more. Medical Supporter provides information and coordination services for patients considering Keytruda-based treatment in Japan.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4